All News
FDA ApprovalFebruary 25, 2026243
FDA Approves New CGRP Antagonist Drug for Chronic Migraine
The FDA has approved a new generation CGRP receptor antagonist for chronic migraine treatment. The drug promises hope for patients experiencing 15 or more migraine days per month.
Nörolojik ilaç gelistirme süreci
New Treatment Option
The newly FDA-approved CGRP antagonist reduces attack frequency by an average of 50% in chronic migraine patients. The drug was tested on 2,500 patients in Phase 3 clinical trials and showed significant results compared to placebo.